Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab versus standard of care in relapsed small cell lung cancer after platinum-based first-line chemotherapy
jRCT2061230044Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Tarlatamab with Standard of Care (2 arms). Primary endpoint: Overall Survival. Started May 2023; status: completed.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2061230044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230044.